Daniel Klamer Selected Research

Phencyclidine (Angel Dust)

3/2011	Prefrontal NMDA receptor antagonism reduces impairments in pre-attentive information processing.
12/2010	Information processing deficits and nitric oxide signalling in the phencyclidine model of schizophrenia.
12/2009	Increased cortical nitric oxide release after phencyclidine administration.
6/2009	The importance of nitric oxide in social dysfunction.
6/2009	Prefrontal GABA(B) receptor activation attenuates phencyclidine-induced impairments of prepulse inhibition: involvement of nitric oxide.
8/2008	Agmatine attenuates the disruptive effects of phencyclidine on prepulse inhibition.
5/2008	Nitric oxide synthase inhibition attenuates phencyclidine-induced disruption of cognitive flexibility.
5/2007	The amino acid L-lysine blocks the disruptive effect of phencyclidine on prepulse inhibition in mice.
4/2007	The atypical antipsychotic, aripiprazole, blocks phencyclidine-induced disruption of prepulse inhibition in mice.
11/2006	Phencyclidine affects memory in a nitric oxide-dependent manner: working and reference memory.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Daniel Klamer Research Topics

Disease

16	Schizophrenia (Dementia Praecox) 04/2011 - 02/2004
5	Cognitive Dysfunction 03/2011 - 07/2006
2	Fragile X Syndrome (Martin Bell Syndrome) 01/2022 - 01/2021
2	Rett Syndrome (Rett's Disorder) 01/2021 - 12/2019
2	Alzheimer Disease (Alzheimer's Disease) 01/2021 - 12/2019
2	Huntington Disease (Huntington's Disease) 01/2018 - 01/2014
2	AIDS-Related Complex (ARC) 11/2014 - 01/2014
1	Neurodevelopmental Disorders 01/2021
1	Pathologic Processes 12/2019
1	Disease Progression 01/2018
1	Alcoholism (Alcohol Abuse) 05/2015
1	Nervous System Diseases (Neurological Disorders) 05/2015
1	Chorea (Rheumatic Chorea) 01/2014
1	Attention Deficit Disorder with Hyperactivity (Attention Deficit Hyperactivity Disorder) 04/2011
1	Brain Diseases (Brain Disorder) 08/2008
1	Psychotic Disorders (Schizoaffective Disorder) 05/2007

Drug/Important Bio-Agent (IBA)

14	Phencyclidine (Angel Dust)IBA 03/2011 - 02/2004
7	Pharmaceutical PreparationsIBA 12/2019 - 02/2004
6	Nitric Oxide (Nitrogen Monoxide)FDA Link 05/2015 - 02/2004
5	N-Methyl-D-Aspartate Receptors (NMDA Receptors)IBA 03/2011 - 04/2005
3	Sigma-1 ReceptorIBA 01/2022 - 12/2019
3	N- dimethyl- 2,2- diphenyl- 3- furanmethanamine hydrochloride tetrahydro-NIBA 01/2022 - 12/2019
3	pridopidineIBA 01/2018 - 01/2014
3	Dopamine (Intropin)FDA LinkGeneric 11/2014 - 04/2011
3	Antipsychotic Agents (Antipsychotics)IBA 04/2011 - 02/2004
3	Nitric Oxide Synthase (NO Synthase)IBA 12/2010 - 02/2004
2	Haloperidol (Haldol)FDA LinkGeneric 11/2014 - 01/2014
2	3,4-Dihydroxyphenylacetic AcidIBA 11/2014 - 01/2014
2	N-Methylaspartate (NMDA)IBA 11/2014 - 04/2005
2	Glutamic Acid (Glutamate)FDA Link 03/2011 - 06/2009
1	Muscarinic Receptors (Muscarinic Acetylcholine Receptor)IBA 12/2019
1	CalciumIBA 12/2019
1	Reactive Oxygen Species (Oxygen Radicals)IBA 05/2015
1	AntioxidantsIBA 05/2015
1	Proteins (Proteins, Gene)FDA Link 11/2014
1	RemoxiprideIBA 11/2014
1	Dopamine D2 Receptor AntagonistsIBA 11/2014
1	Dopamine D2 Receptors (Dopamine D2 Receptor)IBA 11/2014
1	Tetrabenazine (Nitoman)FDA Link 01/2014
1	Messenger RNA (mRNA)IBA 01/2014
1	Lysine (L-Lysine)FDA Link 04/2011
1	Amino Acids FDA Link 04/2011
1	gamma-Aminobutyric Acid (GABA)IBA 06/2009
1	AgmatineIBA 08/2008
1	Neurotransmitter Agents (Neurotransmitter)IBA 08/2008
1	Hallucinogens (Psychedelics)IBA 05/2008
1	Dizocilpine Maleate (Dizocilpine)IBA 04/2005
1	Methylene Blue (Methylthioninium Chloride)FDA Link 02/2004
1	Guanylate Cyclase (Guanylyl Cyclase)IBA 02/2004

Therapy/Procedure

3	Therapeutics 12/2010 - 02/2004